HIV Life Expectancy: What to Expect with Modern Treatment
With early diagnosis and sustained antiretroviral therapy (ART), people with HIV now have a life expectancy nearly identical to the general population.
Key Data
- Large Cohort Studies (NA-ACCORD, ART-CC, UK CHIC): 20-year-old starting ART with CD4 >500 → life expectancy ~78 years (vs. ~81 general). Gap narrows with higher CD4, no hepatitis, non-smoker.
- “Near-Normal” Defined: <5–10 year reduction vs. matched controls, largely attributable to comorbidities (smoking, substance use, HCV, CVD) and late diagnosis—not HIV itself.
- ART Efficacy: Modern INSTI-based regimens (bictegravir, dolutegravir) achieve viral suppression (<50 copies/mL) in >90% within 6 months. Durable, high barrier to resistance.
Factors Influencing Individual Outcomes
| Positive (↑ Life Expectancy) | Negative (↓ Life Expectancy) |
|---|---|
| Early ART initiation (CD4 >500) | Late diagnosis (CD4 <200, AIDS-defining illness) |
| Consistent adherence (viral suppression) | Treatment interruptions, resistance |
| Non-smoker | Smoking (loses 6–8 years; doubles CVD/cancer risk) |
| No/controlled HCV, HBV | Active hepatitis coinfection |
| Healthy weight, exercise, diet | Substance use disorder |
| Regular care (q3–6mo monitoring) | Disengagement from care |
| Mental health support | Untreated depression, stigma isolation |
